The rapid expansion of GLP-1 receptor agonist use into elementary-school-aged children represents one of the more consequential shifts in pediatric medicine in recent years — and new large-scale data now quantify just how dramatic that shift has been. For clinicians, policymakers, and parents alike, understanding who is receiving these medications, and who is not, carries real implications for both safety and equity.
Drawing on the Epic Cosmos database — one of the largest aggregated electronic health record systems in the United States — researchers tracked GLP-1RA prescriptions (liraglutide/Saxenda, semaglutide/Wegovy, and tirzepatide/Zepbound) among children aged 8 to 11 with obesity but without diabetes across a 7.5-year window. The cohort encompassed over 3.5 million children, of whom just 0.6% received a GLP-1RA prescription overall. Yet the trajectory was stark: prescribing prevalence rose from 0.03% in 2019 to 9.3% by mid-2026, a 310-fold increase. Prescribing was meaningfully stratified by age, sex, comorbidity burden, and socioeconomic status. Children with obesity-related comorbidities were prescribed these agents at nearly four times the rate of those without (188.9 vs. ~50 per 10,000). Children with lower social vulnerability were prescribed GLP-1RAs at roughly 55% higher rates than those with high social vulnerability (76.1 vs. 49.2 per 10,000).
This study is observational and cross-sectional by design, making it descriptive rather than causal — it cannot tell us whether prescribing patterns reflect appropriate clinical targeting or structural access barriers. The socioeconomic gradient is especially worth scrutinizing: if less-vulnerable children are receiving these treatments at higher rates, the gap may reflect insurance coverage disparities rather than differential clinical need. Long-term safety data for GLP-1RAs in pre-adolescent children remain limited, and the agents' effects on growth, bone density, and neurodevelopment in this age group are not yet well characterized. This is a confirmatory trend study, not an efficacy or outcomes paper — but its scale makes it a meaningful baseline for monitoring how a fast-moving pharmacological frontier is unfolding in the youngest patients.